Nano-based perivascular intervention sustains a nine-month long-term suppression of intimal hyperplasia in vein grafts
Open Access
- 1 February 2025
- journal article
- research article
- Published by KEAI Publishing in Bioactive Materials
- Vol. 44, 82-96
Abstract
Open vascular reconstructions (OVR), including bypass grafts and dialysis access, are standard treatments for cardiovascular and renal diseases. Unfortunately, OVR often fail largely due to intimal hyperplasia (IH), and there are no clinical methods to prevent this complication. Perivascular drug administration during OVR presents a promising strategy for IH suppression. However, durations of drug release from carriers are generally short whereas sustained efficacy is essential for clinical success. This raises a critical question in clinical translation: can IH suppression be realistically maintained long-term (e.g., over 6 months) with short-term perivascular interventions? To address this question, we modified a rat vein-graft model to prolong IH progression. We then applied Pericelle, a nanoparticle/hydrogel hybrid system that we developed for perivascular delivery of rapamycin, an established IH-inhibitory drug. Surprisingly, despite short (∼3-month) drug release, Pericelle demonstrated IH suppression throughout 3, 6, and 9 months with IH reduced from 115.58 ± 27.89 to 40.34 ± 5.18 at 9 months (P < 0.05, n = 6 rats), as indicated by morphometric analysis. Live animal ultrasonography showed the same trend. Consistently, histone-3 lysine-27 trimethylation, an epigenetic mark associated with IH progression, was decreased at 6 months after Pericelle treatment. Moreover, Pericelle exhibited promising efficacy in mitigating IH in a porcine model of arteriovenous fistula that mimics dialysis access. These results suggest that Pericelle-mediated suppression of IH in rat vein-grafts extends much beyond drug release, offering potential solutions to longstanding translational challenges in reducing OVR failure.Keywords
This publication has 66 references indexed in Scilit:
- Neointima abating and endothelium preserving — An adventitia-localized nanoformulation to inhibit the epigenetic writer DOT1LBiomaterials, 2023
- Nitric oxide releasing nanomatrix gel treatment inhibits venous intimal hyperplasia and improves vascular remodeling in a rodent arteriovenous fistulaBiomaterials, 2021
- An adventitial painting modality of local drug delivery to abate intimal hyperplasiaBiomaterials, 2021
- Nullifying epigenetic writer DOT1L attenuates neointimal hyperplasiaAtherosclerosis, 2020
- Perivascular medical devices and drug delivery systems: Making the right choicesBiomaterials, 2017
- Bromodomain Blockade for Intimal Hyperplasia — A Good BET?EBioMedicine, 2015
- BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid ArteriesEBioMedicine, 2015
- A rapamycin-releasing perivascular polymeric sheath produces highly effective inhibition of intimal hyperplasiaJournal of Controlled Release, 2014
- Extravascular perivenous fibrin support leads to aneurysmal degeneration and intimal hyperplasia in arterialized vein grafts in the ratLangenbeck's Archives of Surgery, 2008
- Kinetics of vein graft hyperplasia: Association with tangential stressJournal of Vascular Surgery, 1987